Publications
103
Citations
2,712
Est. group size
~2
Recurring co-author estimate
Active years
31
Publishing since 1996
Typically publishes in teams of ~14 · 6% small-team papers (≤3 authors) · across 10 venues
- Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States
Journal of Onco-Nephrology · 2026
- Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)
Blood · 2025
- AST-KPCOP Survey on Clinical Practice Patterns in Kidney Transplants for Plasma Cell Dyscrasia
American Journal of Transplantation · 2025
- Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
Blood · 2024
- A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209
Blood · 2024
- Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma
Leukemia · 2022
- Daratumumab Interferes with Allogeneic Crossmatch Impacting Immunological Assessment in Solid Organ Transplantation
Journal of Clinical Medicine · 2022
- Daratumumab Interferes with Histocompatibility Crossmatch Impacting Immunological Assessment in Solid Organ Transplantation
Preprints.org · 2022
- First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood · 2020
- A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)
Blood · 2020
- DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
Seminars in Hematology · 2020
- Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)
Blood · 2019
- Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
Blood · 2019
- A family-centered intervention for the transition to living with multiple myeloma as a chronic illness: A pilot study
Applied Nursing Research · 2017
- Management of multiple myeloma in older adults: Gaining ground with geriatric assessment
Journal of Geriatric Oncology · 2016
- Blood×17
- Journal of the National Comprehensive Cancer Network×7
- New England Journal of Medicine×1
- The Lancet Haematology×1
- PubMed×1
- Craig E. Cole
Medicine · University of Michigan
- Matthew J. Pianko
Medicine · University of Michigan
- Rafat Abonour
Medicine · Indiana University
- Brian A. Walker
Medicine · Indiana University
- Camille Herzog
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile